What question did this study set out to answer?

This research aims to characterize TP53 and RB1 alterations in pediatric acute myeloid leukemia and their prognostic implications.

TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial identifies TP53 and RB1 genetic changes in pediatric acute myeloid leukemia, suggesting risk stratification for treatment.

This research aims to characterize TP53 and RB1 alterations in pediatric acute myeloid leukemia and their prognostic implications.
Performed next-generation sequencing in 328 pediatric AML patients from the Japanese AML-05 trial.
Identified genetic alterations and related prognostic outcomes.
Analyzed gene expression profiles and conducted Kaplan-Meier analysis.
TP53 alterations were found in 2.1% of patients, with 5-year OS at 14.3% compared to 71.4% for those without (p < 0.001).
RB1 alterations occurred in 1.8% of patients, showing 5-year OS at 0% compared to 71.8% without (p < 0.001).
High expression of SLC2A5, KCNAB2, and CD300LF correlated with poor OS in non-core-binding factor AML patients (p < 0.001).

Hara et al. (2023) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial identifies TP53 and RB1 genetic changes in pediatric acute myeloid leukemia, suggesting risk stratification for treatment.